Printer Friendly

Global Diabetic Neuropathy Market 2014-2018: Key Vendors are Eli Lilly and Co, Janssen Pharmaceuticals and Pfizer Inc.

DUBLIN, Aug. 8, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Diabetic Neuropathy Market 2014-2018" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769 R&D activities in the Diabetic Neuropathy sector are growing in terms of an increase in the number of mergers and acquisitions. Big pharmaceutical companies take up later-stage products from small companies, where efficacy has already been demonstrated, thereby cutting down initial R&D expenditure.

For instance, in March 2013, BioDelivery Sciences International Inc. in-licensed a patented topical formulation of clonidine gel from Arcion Therapeutics Inc. for the treatment of indications including diabetic neuropathy. In July 2013, Acorda Therapeutics acquired two candidates for neuropathic pain including NP-1998, a topical capsaicin solution, from NeurogesX Inc. In-licensing by big pharmaceutical companies, in turn, diverts funds to be spent by the smaller companies on marketing and commercialization to R&D development. According to the report, the Global Diabetic Neuropathy market is driven by several factors, of which the increase in the global diabetic population is one of the major drivers. The incidence and prevalence rate of diabetes is growing continuously, mainly because of the adoption of a sedentary form of life and unhealthy eating habits accompanied by increased life expectancy. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Geographical Segmentation 08. Buying Criteria 09. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Trends and their Impact 15. Vendor Landscape 16. Key Vendor Analysis 17. Pipeline Analysis 18. Other Reports in this Series Companies Mentioned:

* Eli Lilly and Co

* Janssen Pharmaceuticals

* Pfizer

* Actavis

* Cephalon

* MEDA Pharma GmbH & Co

For more information visit http://www.researchandmarkets.com/research/q8x6s6/global_diabetic

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net

COPYRIGHT 2014 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Geographic Code:4EUIR
Date:Aug 8, 2014
Words:437
Previous Article:Global Recruitment Software Market 2014-2018: Key Vendors are Kenexa, Lumesse, Oracle Taleo and SuccessFactors.
Next Article:Enterprise Acquires Burnt Tree to Expand its Commercial Vehicle Rental Business.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters